By John Meyer, consultant in business and finance – Eurasia Business News, October 10, 2025. Article no. 1825
AstraZeneca is set to formalize a Most Favored Nation (MFN) drug pricing agreement with President Donald Trump. This deal follows a similar agreement Trump made with Pfizer and is part of an effort to reduce drug prices in the U.S. by aligning prices with those paid in other developed countries.
As part of the agreement, AstraZeneca will sell discounted drugs on the TrumpRx platform, which offers direct-to-consumer drug sales at lower prices. The company will also invest $50 billion in U.S. drug manufacturing and research and development, helping it avoid tariffs that Trump threatened against pharmaceutical imports.
The announcement was planned for October 10, with AstraZeneca CEO Pascal Soriot expected to appear in the Oval Office alongside President Trump. The deal is designed to bring American drug prices closer to international levels, aiming to benefit low-income patients and Medicaid recipients while encouraging domestic production. Some drugs under this agreement may see price cuts up to 85%, and AstraZeneca’s participation aligns with Trump’s broader health policy priorities to tackle high drug costs and promote “America First” manufacturing strategies.
A Most Favored Nation (MFN) pricing agreement in the context of drug pricing is a policy where the United States aligns the prices it pays for certain prescription drugs with the lowest prices paid by other developed countries. Specifically, under MFN drug pricing, Medicare and other government programs would pay no more for select brand-name drugs than the lowest GDP-adjusted price paid by a comparable high-income country, preventing Americans from overpaying relative to international prices.
Our community already has 170,000 readers, joins us !
Subscribe to our Telegram channel
Follow us on Telegram, Facebook and Twitter
© Copyright 2025 – Eurasia Business News. Article no. 1825
Eurasia Business News 